CEOS Stock Overview
Engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Psykey, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.024 |
| 52 Week High | US$0.055 |
| 52 Week Low | US$0.0077 |
| Beta | 0 |
| 11 Month Change | -24.30% |
| 3 Month Change | 41.25% |
| 1 Year Change | 54.05% |
| 33 Year Change | -62.16% |
| 5 Year Change | 580.00% |
| Change since IPO | -99.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| CEOS | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 13.3% | -0.9% | 0.9% |
| 1Y | 54.0% | 0.6% | 32.3% |
Return vs Industry: CEOS exceeded the US Healthcare Services industry which returned 0.6% over the past year.
Return vs Market: CEOS exceeded the US Market which returned 32.3% over the past year.
Price Volatility
| CEOS volatility | |
|---|---|
| CEOS Average Weekly Movement | 26.3% |
| Healthcare Services Industry Average Movement | 9.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CEOS's share price has been volatile over the past 3 months.
Volatility Over Time: CEOS's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Kate Monroe | www.psykeyworld.com |
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes.
Psykey, Inc. Fundamentals Summary
| CEOS fundamental statistics | |
|---|---|
| Market cap | US$7.81m |
| Earnings (TTM) | -US$5.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CEOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEOS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.01m |
| Earnings | -US$5.01m |
Last Reported Earnings
Sep 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CEOS perform over the long term?
See historical performance and comparison